ArticleFrontiers in cellular and infection microbiology2026
VSIG2 is associated with an immune-cold microenvironment and reduced response to PD-1 blockade in bladder cancer.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer is one of the most common malignancies worldwide, and only a subset of patients derives durable benefit from immune checkpoint blockade. An immune-cold tumor microenvironment, characterized by limited immune infiltration and impaired antitumor activity, is a major barrier to immunotherapy efficacy. However, the tumor-intrinsic factors that contribute to immune exclusion in bladder cancer remain incompletely understood. This study aimed to investigate the role of VSIG2 in shaping the immune microenvironment and immunotherapy response in bladder cancer. Methods: Integrative analyses were performed using bulk transcriptomic data, a Xiangya validation cohort, public single-cell RNA-seq datasets, and a Xiangya single-cell immunotherapy cohort. Immune-related transcriptional programs, immune cell infiltration, and cancer immunity cycle activity were evaluated by differential expression, enrichment, and immune deconvolution analyses. The cellular source and biological features of VSIG2 were further characterized at single-cell resolution. Clinical relevance was assessed by immunohistochemistry and response-associated analyses in immunotherapy-treated samples. Functional validation was performed in an MB49 syngeneic mouse model with VSIG2 knockdown combined with anti-PD-1 treatment. Results: VSIG2 was associated with an immune-cold phenotype in bladder cancer across multiple independent cohorts. In bulk transcriptomic analyses, VSIG2-high tumors exhibited reduced activity across several steps of the cancer immunity cycle, decreased infiltration of T cells, cytotoxic lymphocytes, and NK cells, and suppression of inflammatory, chemokine-related, and antigen-presentation programs. These findings were independently validated in the in-house cohort. Single-cell analyses showed that VSIG2 was predominantly enriched in malignant epithelial cells and marked tumor cell states characterized by weaker antigen-presentation, interferon-response, and immune interaction programs. In the in-house single-cell immunotherapy cohort, lower VSIG2 expression was associated with immunotherapy response and a more inflamed immune contexture. Conclusions: VSIG2 is a tumor-associated molecule linked to immune exclusion and reduced responsiveness to PD-1 blockade in bladder cancer. Elevated VSIG2 expression marks malignant cell states with impaired immune engagement, whereas targeting VSIG2 enhances antitumor immunity and improves immunotherapy efficacy
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.